Stock analysis · Bull Rankings model

VRDN analysis

Viridian Therapeutics Inc — Biotechnology. Scored on the same transparent 7-signal model behind the daily rankings.

★
VRDN
Viridian Therapeutics Inc · Biotechnology
FCF-$304mF
Rev+23382.8%A
D/E0.12A-
P/S24.3xD
PEG——
60Score
$17.00
1Y Target$22.95Near-term target
5Y Target$34.19Compound horizon
10Y Target$88.98Long-dated conviction
FCF-$304mTTM · 03/26
F
FCF is negative (-$304m) — cash-burning phase; acceptable only for pre-profit spec names · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+23382.8%TTM YoY
A
Revenue +23382.8% — hypergrowth, top decile
D/E0.12
A-
D/E 0.12 — conservative leverage, strong balance sheet
P/S24.3x
D
P/S 24.3x — extreme, prices in flawless execution
PEG—proxy
—
PEG not meaningful — earnings growth negative or data unavailable · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Why now
Biotechnology · market cap $1.8b. Down 50% from 52-week high of $34.29 — deep drawdown territory. Revenue growing +23383% — in hypergrowth territory.
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Free cash flow is negative (-$304m) — capital raises or debt issuance likely required; dilution / leverage risk. Currently unprofitable (margin -508.5%) — path to GAAP profitability is the core thesis risk. Down 50% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon
1-3 yr $22.95 (structural (no analyst coverage)) — catalyst-driven; binary events dominate. 5 yr $34.19 — requires the platform / technology to reach commercial scale. 10 yr $88.98 — return distribution heavily skewed.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Position sizing · VRDN
Shares to buy
117
Position size
$1,989
4.0% of portfolio
Stop price
$12.75
25% below $17.00
$ at risk
$500.00
1% of portfolio

Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.

Analyze another ticker →